KR20230061421A - Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법 - Google Patents

Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법 Download PDF

Info

Publication number
KR20230061421A
KR20230061421A KR1020237010275A KR20237010275A KR20230061421A KR 20230061421 A KR20230061421 A KR 20230061421A KR 1020237010275 A KR1020237010275 A KR 1020237010275A KR 20237010275 A KR20237010275 A KR 20237010275A KR 20230061421 A KR20230061421 A KR 20230061421A
Authority
KR
South Korea
Prior art keywords
antibody
upregulated
binding fragment
aml
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010275A
Other languages
English (en)
Korean (ko)
Inventor
요하네스 데하드
애나 헐트버그
줄리 제이콥스
피오트르 자브로키
클레이톤 스미스
크레이그 조르단
Original Assignee
아르제넥스 비브이
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르제넥스 비브이, 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 filed Critical 아르제넥스 비브이
Publication of KR20230061421A publication Critical patent/KR20230061421A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/57426—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237010275A 2020-08-29 2021-08-27 Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법 Pending KR20230061421A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072113P 2020-08-29 2020-08-29
US63/072,113 2020-08-29
PCT/EP2021/073816 WO2022043538A1 (en) 2020-08-29 2021-08-27 Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
KR20230061421A true KR20230061421A (ko) 2023-05-08

Family

ID=77821706

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010275A Pending KR20230061421A (ko) 2020-08-29 2021-08-27 Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법

Country Status (10)

Country Link
US (1) US20240182590A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204098A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023539493A (cg-RX-API-DMAC7.html)
KR (1) KR20230061421A (cg-RX-API-DMAC7.html)
CN (2) CN122351461A (cg-RX-API-DMAC7.html)
AU (1) AU2021334165A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188634A1 (cg-RX-API-DMAC7.html)
IL (1) IL300996A (cg-RX-API-DMAC7.html)
MX (1) MX2023002318A (cg-RX-API-DMAC7.html)
WO (1) WO2022043538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2025541170A (ja) * 2022-12-08 2025-12-18 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 急性骨髄性白血病のベネトクラクス／低メチル化剤／抗ｃｄ７０剤による治療に対する耐性又は反応性を特定する方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
CN109563096A (zh) 2016-06-09 2019-04-02 雷迪博士实验室有限公司 固体形式的维奈托克和用于制备维奈托克的方法
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US20190177317A1 (en) 2016-08-12 2019-06-13 Mylan Laboratories Limited Process for the preparation of venetoclax
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Also Published As

Publication number Publication date
CN122351461A (zh) 2026-07-10
AU2021334165A1 (en) 2023-03-02
MX2023002318A (es) 2023-05-19
IL300996A (en) 2023-04-01
CN116249519A (zh) 2023-06-09
CA3188634A1 (en) 2022-03-03
US20240182590A1 (en) 2024-06-06
WO2022043538A1 (en) 2022-03-03
AU2021334165A8 (en) 2023-03-16
EP4204098A1 (en) 2023-07-05
JP2023539493A (ja) 2023-09-14

Similar Documents

Publication Publication Date Title
US20250152707A1 (en) Cd70 combination therapy
CN106459184B (zh) 与抗cd38抗体联用的组合疗法
ES2974678T3 (es) Uso del anticuerpo anti CD70 ARGX-110 para tratar la leucemia mieloide aguda
US20240182590A1 (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
WO2019189780A1 (ja) 癌の治療及び／又は予防用医薬組成物
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
HK40089820A (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2
CA3117282C (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40091007B (en) Cd70 and a bcl-2 inhibitor combination therapy for treating acute myeloid leukemia
HK40091007A (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40052961B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40052961A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
CN119546640A (zh) 用于治疗癌症的包含SIRPα融合蛋白和抗CD19抗体的组合疗法
HK40049607B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40049607A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
EA049354B1 (ru) Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза
BR122024010998A2 (pt) Uso de um anticorpo anti-cd38

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902